Mergers & Acquisitions - Patents

Filter

Current filters:

Patents

Popular Filters

Patent expiry and increasing generic competition is expected to make a handful of mega deals happen

Patent expiry and increasing generic competition is expected to make a handful of mega deals happen

13-05-2014

The challenges posed by expiring patents, the global economic slowdown, and price premium pressures are…

Mergers & AcquisitionsPatentsPharmaceutical

Indian drugmakers readying for next “Patent cliff”

24-02-2014

The strategic drug reviews, as well as mergers and acquisitions – such as Actavis buying out Forest…

Asia-PacificGenericsIndiaMergers & AcquisitionsPatentsPharmaceuticalRegulation

US FTC finalizes amendments to the premerger notification rules on patent right transfers

07-11-2013

The US Federal Trade Commission yesterday (November 6) issued final changes to the premerger notification…

LegalMergers & AcquisitionsNorth AmericaPatentsPharmaceutical

Generics briefs: Actavis/Warner Chilcott M&A delay; Canasa patent challenge

11-07-2013

US generics major Actavis (NYSE: ACT) and Ireland-based Warner Chilcott (Nasdaq: WCRX) have each received…

ActavisAptalis PharmaCanasaGenericsLegalMergers & AcquisitionsMylan LaboratoriesNorth AmericaPatentsWarner Chilcott

Actavis in OxyContin patent settlement; Valeant takeover bid "on hold"?

29-04-2013

US generic major Actavis (NYSE: ACT) has entered into an agreement with privately-held Purdue Pharma…

ActavisGenericsMergers & AcquisitionsNeurologicalNorth AmericaOxyContinPatentsPurdue PharmaValeant Pharmaceuticals

Analysis of China government incentives for pharma

27-03-2013

China remains an attractive target for pharmaceutical research and manufacturing, and major players from…

Asia-PacificLicensingMarkets & MarketingMergers & AcquisitionsPatentsPharmaceutical

Cipla prevails in Sutent patent dispute with Pfizer; puts hold on Cipla Medpro deal

12-02-2013

The Indian patent office has again ruled in favor of domestic drugmaker Cipla (BSE: 500087), reinstating…

Asia-PacificCiplaCipla MedproGenericsLegalMergers & AcquisitionsOncologyPatentsPfizerRest of the WorldSutent

Actavis reportedly to be acquired by Watson; debuts generic Zomig

22-03-2012

Icelandic generic drugmaker Actavis is said to be in talks to be acquired by US peer Watson Pharmaceuticals…

ActavisAstraZenecaEuropeGenericsMarkets & MarketingMergers & AcquisitionsNeurologicalPatentsWatson PharmaceuticalsZolmitriptanZomig

COMPANY SPOTLIGHT

Menarini

Back to top